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Abstract 
In New Zealand, it is common for young people to mix 1-benzylpiperazine (BZP) 
containing ‘party pills’ and ethanol (drinking alcohol). However, there is no scientific 
literature which compares the individual and combined long-term effects of these 
substances. Therefore, the aim of this study was to provide a comparison of BZP and 
ethanol’s individual and combined effects on adulthood behaviour following repeated 
adolescent exposure. To investigate this 40 male and 40 female adolescent rats received 
daily exposure (post natal days 41 – 50) to BZP (10 mg/kg) and/or ethanol (2 g/kg) or 
saline vehicle (1 ml/kg) via intraperitoneal injection. Animals were tested in a Y maze, 
light/dark emergence box, and an open field during early adulthood (PND 78 – 81) and 
again during mid-adulthood (PND 117 – 120). Results found females treated with alcohol 
ambulated less in the open field. Interestingly, no other behavioural differences between 
the treatment groups were observed. Overall, it appeared that adolescent exposure to BZP 
and/or alcohol did not have long-term behavioural consequences, at least in rats. This 
finding was most likely due to the narrow range of testing ages adopted in the study.  
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1.0 Introduction 
1.1 General Overview 
 Adolescence is an exciting and vulnerable period when young people make the 
gradual transition from childhood to adulthood. During adolescence, there is an increase 
in risk-taking behaviour such as the initiation of drug use (Brecht, Greenwell, & Anglin, 
2007; Spear, 2000). Consuming such substances during this period can have detrimental 
developmental effects later in life (Casey, Giedd, & Thomas, 2000). As a result, there is a 
need for research into the effects of adolescent drug exposure with an emphasis on the 
substances current young people are commonly taking.  
In view of this issue, the use of ‘legal party pills’ is common amongst New 
Zealanders with one in five aged 13 – 45 years reporting having used them at least once 
and 38% of young adults aged 20 – 24 having used them in the past 12 months (Wilkins, 
Girling, Sweetsur, Huckle, & Haukau, 2006). Party pills are taken for their stimulant 
effects produced by the active ingredient 1-benzylpiperazine. Party pills are marketed as a 
safer legal alternative to the methamphetamine class of drugs (Johnstone, Lea, Brennan, 
Schnek, Kennedy, & Fitzmaurice, 2007). However, there is little known about the longer-
term outcomes of exposure to 1-benzylpiperazine to support a harm reduction hypothesis. 
Therefore, research on the longer-term outcomes of adolescent exposure to party pills is 
required.  
 In addition to party pills, ethanol (drinking alcohol) is a drug regularly consumed 
by young New Zealanders. Stefanogiannis, Mason, and Yeh (2007) found the most 
frequent alcohol users were those aged 18 – 24 years. The World Health Organization 
(WHO) recommends males should consume no more than six standard drinks and 
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female’s no more than four standard drinks on a single drinking occasion. Consumption 
in excess of this recommendation is considered drinking large amounts of alcohol. 
Unfortunately, one in two New Zealanders aged 18 – 24 and one in five aged 12 – 17 
exceed the WHO recommendations on a usual drinking occasion. In view of this, 
research on the longer-term outcomes of adolescent exposure to alcohol is needed. 
 In New Zealand poly drug use of party pills and alcohol is common. Over 90% of 
party pill users have reported using both alcohol and party pills together at some point. In 
addition, one in three users consumes more alcohol when using party pills than they 
would otherwise (Wilkins et al., 2006). This poly drug use by New Zealand adolescence 
could have detrimental developmental effects. 
Currently there is no scientific literature on the combined effects of 1-
benzylpiperazine and alcohol. Therefore, the primary aim of this thesis was to provide an 
assessment of longer-term behavioural outcomes following adolescent exposure to 1-
benzylpiperazine and alcohol both alone and in combination thereby making an original 
contribution to the scientific literature on the effects of these drugs. 
 
1.2 Substance use and addiction 
 To provide an understanding of the possible consequences of repeated exposure to 
1-benzylpiperazine (BZP) and alcohol, the diagnostic criteria for Substance Abuse and 
Substance Dependence disorder is provided below. However, for an individual to become 
an abuser or an addict of these substances they must first go through an experimental 
phase. Therefore, the behavioural and physiological mechanisms of Substance Abuse and 
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Substance Dependence are briefly presented. These disorders can lead to significant 
personal, occupational, social, and interpersonal impairment. 
 Substance Abuse and Substance Dependence are two types of Substance Use 
Disorder. The differences between these disorders need to be clearly defined. The most 
prominent tool for diagnosing Substance Use Disorders is The Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV; APA, 1994). The DSM-IV defines Substance 
Abuse as a maladaptive pattern of substance use manifested by recurrent and significant 
adverse consequences related to repeated use of the substance. Associated impairments 
include (but are not limited to) intoxication at work or school and the continued use of the 
substance in hazardous situations such as driving. To meet the criteria for Substance 
Abuse disorder the symptoms must not meet the criteria for Substance Dependence 
disorder. Additionally, the individual in the past 12 months must present one or more of 
the four symptoms described in the manual.  
In comparison, the DSM-IV defines Substance Dependence disorder as a cluster 
of cognitive, behavioural, and physiological symptoms indicating that the individual 
continues use of the substance despite significant substance related problems. To meet 
the criteria for Substance Dependence disorder an individual must meet three or more of 
the seven symptoms outlined in the manual. Such symptoms include having developed 
tolerance to the substance and withdrawal symptoms when discontinued use of the 
substance occurs (see the DSM-IV for a full description of all symptoms; APA, 1994). 
Importantly, before an individual can develop a substance use disorder they must first 
experiment with the drug. 
 
 
 5
1.2.1 Initiation of Drug Use 
The factors which contribute to the initiation of drug use need to be discussed to 
understand why young New Zealanders with no history of drug use often experiment 
with BZP and/or alcohol. The reasons why an individual experiments with a substance 
are varied and complex. Genetics and family environment are biological factors that are 
important aetiological variables which contribute to the initiation of substance use 
(Weinberg, Rahdert, Colliver, & Glantz, 1998). Studies of monozygotic and dizygotic 
twins have found both genetics and the family environment play an important role in the 
use and clinical diagnosis of substance abuse/dependence (Maes et al., 1999; van den 
Bree, Johnson, Neale, & Pickens, 1998). Recent evidence from twin studies (e.g. Xian et 
al., 2000) suggests the major genetic predisposition to drug use and dependence is 
heritability. Interestingly, this predisposition appears to be stronger with males than 
females (Wagner & Anthony, 2001; Xian et al., 2000).  
In addition to genetic risk factors, there are several important environmental 
factors which contribute to young people experimenting with drugs. These risk factors 
include peer pressure, association with antisocial peers, substance availability, individual 
expectations of the substance being used, and economic factors (Andrews & Bonta, 2003; 
Crombag & Robinson, 2004; van den Bree et al., 1998). Exposing adolescents to one or 
more of these risk factors increases their likelihood of experimenting with drugs. Many 
young adults in New Zealand experiment with BZP and alcohol. Once substance 
experimentation has been initiated individuals can develop an addiction. To understand 
the aetiology of substance use disorders, the mechanisms of addiction will be discussed in 
the next section.  
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1.2.2 Mechanisms of Addiction 
The mechanisms which initially lead to substance use disorders are behavioural. 
For an individual to become dependent on a drug the substance must first reinforce the 
individual’s behaviour (Cardinal & Everitt, 2004; Carlson, 2004). At first, the reinforcing 
effects of drugs are mediated via positive reinforcement. When behaviour (e.g. substance 
use) is immediately followed by a reward (e.g. pleasurable feelings, gratification, relief of 
stress), that behaviour is reinforced (Kazdin, 2001; Robbins & Everitt 1999). For 
example, nicotine rapidly provides pleasurable feelings to the user thus reinforcing the 
person’s smoking behaviour (Coe et al., 2005; Keating & Siddiqui, 2006). For drugs of 
abuse, the mechanisms which reinforce substance use behaviour are neurobiological. 
The positive reinforcing properties of drugs of abuse are mediated by inducing 
changes in the neural circuits utilized for the reward values of natural reinforcers such as 
food, water, and sex (Cami & Farre, 2003). This neural system provides individuals with 
a motivation to obtain such rewards (Crombag & Robinson, 2004; Chiara, 1995). The 
dopamine hypothesis of addiction suggests most (if not all) addictive substances exert 
their psychoactive actions (either directly or indirectly) on the neurotransmitter dopamine 
(DA, Cardinal & Everitt, 2004; Robbins & Everitt, 1999). Increased DA levels within the 
mesolimbic DA system have been associated with the euphoric and addictive properties 
of drugs (Carlson, 2004; Julien, 2001). The mesolimbic DA system originates in the 
ventral tegmental area (VTA) of the midbrain and projects to forebrain structures such as 
the nucleus accumbens (NA) and the prefrontal cortex (PFC). The VTA and its associated 
neural circuitry has been shown to play a critical role in reinforcement. For example, 
when nicotine binds with α4β2 receptors in the VTA the DA reward pathway is activated. 
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This activation results in increased mesolimbic DA levels. This increase in DA levels 
provides the smoker with pleasurable feelings which in turn reinforce smoking behaviour 
(Jorenby et al., 2006; Rollem et al., 2006; Tsai et al., 2007). In addition, Bozarth and 
Wise (1981) found rats would self-administer morphine. In their study, subjects could 
self-administer morphine directly into the VTA by pressing a lever. They found subjects 
response rates were stable and exceeded those of ‘yoked’ controls. Self-administration 
was blocked by the μ-opioid receptor antagonist naloxone. This finding suggests 
morphine’s reinforcing properties are mediated via activation of μ-opioid receptors in the 
VTA. This activation causes an increase in mesolimbic DA levels which is common with 
drugs of abuse.  
Even though increased DA levels appear to be primarily responsible for the 
reinforcing effects of drugs (see Chiara, 1995 for a review), serotonin (or 5-
hydroxytryptamine, 5-HT) may also be important. Rocha et al. (1998a & 1998b) reported 
two studies with cocaine which challenged the dopamine hypothesis. Cocaine acts by 
blockading dopamine transporter’s (DAT) that are responsible for the re-uptake of DA 
from the synaptic cleft. Therefore, cocaine blockade of DATs leads to increased 
extracellular DA. This effect is considered by many to be the primary cause of the 
reinforcing and addictive properties of cocaine (Rocha, 1998a). Therefore, animals 
lacking DATs would have high levels of extracellular DA and should not receive any 
reward or reinforcement from cocaine administration.  
In their study, Rocha et al. (1998a) investigated whether or not mice genetically 
lacking the presynaptic DAT would self-administer cocaine. Interestingly they found 
cocaine self-administration occurred in these subjects at levels considered to be 
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reinforcing. Mapping of cocaine’s binding sites suggested 5-HT was responsible for 
cocaine’s reinforcement.  
In a further study, Rocha et al. (1998b) investigated cocaine self-administration 
behaviour in mice lacking the postsynaptic 5-HT1B receptor. They found the effects of the 
drug in these subjects were greater than in control animals, and they were more motivated 
to self-administer. This occurs as 5-HT acts through many receptors to modulate the 
mesolimbic DA circuit. The 5-HT1B receptor is expressed on the terminal buttons of γ-
aminobutyric acid (GABA) striatal neurons. These GABA neurons project to the VTA. 
GABAs role is to inhibit the release of DA in this area. Therefore, the lack of 5-HT 
activation of GABAergic striatal neurons causes additional stimulation of DA releasing 
neurons during cocaine use. Accordingly, this finding suggests 5-HT can also antagonize 
the reinforcing effects of cocaine. In summary, the DA reward system is shown to be the 
primary contributor to the acquisition of drug addiction, but some studies have shown the 
5-HT system to also be involved. 
Thus far positive reinforcement has been argued as the mechanism which leads to 
drug addiction. However, once an addiction has been acquired negative reinforcement is 
responsible for maintaining the behaviour. When a behaviour (e.g. drug taking) alleviates 
negative symptoms (e.g. relief of stress and anxiety) that behaviour is then reinforced as 
it has provided relief (Kazdin, 2001). For an individual to experience negative side 
effects during a period of substance abstinence they must have developed tolerance to the 
drug and then manifested withdrawal symptoms.  
Tolerance is a state of progressively decreasing responsiveness to a drug. When a 
substance is repeatedly administered larger doses are required to generate the original 
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effect (e.g. euphoria, relief of stress) which the original smaller dose produced (Julien, 
2001). This occurs as drug use causes a decrease in receptor sensitivity known as down 
regulation. Down regulation is the brain’s compensatory mechanism for counteracting the 
drug’s effects (Carlson, 2004). For example, as use of morphine progresses, the μ-opioid 
receptor becomes less sensitive to the drug. Therefore, increasingly larger doses of the 
substance are required to produce its pharmacologic effects (Bozarth & Wise, 1981). 
Once an individual has acquired substance tolerance they will experience withdrawal 
symptoms during a period of abstinence (Swann, Jack, Valdes, Ring, Ton, & Curry, 
2007). 
Withdrawal symptoms essentially reflect the opposite acute effects of the drug 
(Piper, et al., 2008). For example, cocaine produces feelings of pleasure, calmness, and 
euphoria. However, when an individual goes through cocaine withdrawal they experience 
anxiety and dysphoria. These symptoms lead to cravings for the drug to alleviate the 
discomfort they produce (Julien, 2001). When the user re-administers the drug the 
negative symptoms are relieved and the behaviour is reinforced (Lopez-Pation, Yu, 
Cabral, & Zhdanova, 2008).  
Withdrawal symptoms for stimulant drugs are probably a result of low DA levels 
arising from the brain’s compensation for the effects of the substance. The sudden 
absence of the substance means the required level of DA is no longer being released in 
the brain. This lack of DA produces withdrawal symptoms. Withdrawal symptoms are 
argued to be a key contributor to relapse during abstinence attempts (Keating & Siddiqui, 
2006). Importantly, withdrawal from depressants can be different from stimulant 
withdrawal. For example, the rewarding properties of alcohol are mediated via release of 
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DA in the NA (Littleton, 1998). However, alcohol also interacts with other 
neurotransmitters (discussed in the Ethanol section). Alcohols down regulation of these 
neurotransmitters can lead to hallucinations, seizures and even death during a withdrawal 
episode if left untreated (Bayard, McIntyre, Hill, & Woodside, 2004) As a result, 
neurotransmitter systems additional to DA play a role in the negative reinforcing 
properties of depressants such as alcohol. Therefore, the role of negative reinforcement is 
to maintain drug addiction to alleviate the negative symptoms associated with 
withdrawal.  
In summary, substance abuse and dependence are debilitating conditions which 
can be avoided by understanding the consequences of drug use. When an individual 
experiments with a substance they risk developing a substance use disorder. Once drug 
use has been initiated positive reinforcement via the DA reward pathway and possibly the 
5-HT system can lead the individual to a substance use disorder. When addiction has 
been acquired negative reinforcement via tolerance and withdrawal maintain drug use. 
The long-term outcomes of drug use could have detrimental effects later in life. 
Therefore, I argue substances which are currently being taken by young people that have 
the potential for abuse should be thoroughly investigated.  
 
1.3 Neurodevelopment: The adolescent point of vulnerability 
 Adolescence is defined as a period of gradual transition from childhood to 
adulthood. This period involves undergoing developmental challenges to attain the skills 
necessary to survive independently of parental caregivers (Spear, 2000).  Importantly, the 
adolescent period extends well beyond puberty. Puberty is the onset of sexual maturation 
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and is sometimes considered the beginning of the adolescent period. Once sexual 
maturation is acquired the brain continues to develop (Spear, 2000). The duration of 
adolescent brain development (known as the periadolescent period) is unclear. The onset 
of the periadolescent period begins about age 12 in humans and can extend to as late as 
20 – 25 years of age. During this phase the brain continues to undergo maturational 
changes (McFadyen, Brown, & Carrey, 2002; Spear, 2000). Therefore, the periadolescent 
stage of development is a ‘brain in transition’ period. This section will argue that 
interference with the brain during this transitional period can have consequences later in 
life. 
 The adolescent period is a time when individuals engage in risky sensation and 
novelty seeking behaviours. Engaging in such behaviours provides the opportunity to 
explore new situations and reinforcers. Taking part in such behaviours with peers 
promotes independence from parental caregivers (Spear, 2000). Participation in risky 
behaviours is considered a normal part of adolescent development. Such behaviour 
includes minor criminal behaviour, and use of drugs. Therefore, some experimentation 
with drugs is considered a normal part of adolescent development (Arnett, 1992). 
 The periadolescent period is characterised by regionally specific 
neurodevelopment. During this stage the brain undergoes a large amount of maturation. 
There are changes in the brain’s neurochemistry and neuroendocrine control (Smith, 
2003). Cellular events include an overproduction of synapses and receptors and increased 
myelination. Synapses that fail to make strong connections are pruned via apoptosis. This 
reduction process results in a loss of up to 40% of the synapses (Andersen & Navalta, 
2004). Additionally, the brain experiences maturation of specific anatomical structures. 
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Structures which experience notable development are the nucleus accumbens (NA), 
amygdala, hippocampus, and the prefrontal cortex (PFC, Carlson, 2004). Each structure 
serves a specific function. In particular, the NA is involved with motivation, reward, and 
addiction. The amygdala regulates emotional reactions. The hippocampus is responsible 
for the formation of memories, and the PFC is involved in abstract reasoning and making 
judgements (Cassey, et al. 2000; Carlson, 2004; Chambers, Taylor, & Potenza, 2003; 
Spear, 2000). In addition, some sex differences in neurodevelopment are observed. For 
example, although females reach peak levels of cortical gray matter earlier than males, 
total cerebral volume is 9% larger in males than in females. The left amygdala of male 
brains increases significantly whereas female’s experience a considerable increase in the 
size of the right hippocampus. Many of the anatomical differences observed in 
adolescence are still present in adulthood (Andersen, 2003; Cassey et al., 2000, Smith, 
2003). In other words, adolescents undergo sex-specific neurodevelopment. 
 From observations of normal adolescent development it is seen why young people 
experiment with drugs, and also the potential consequences of such experimentation. 
Firstly, young people are motivated to seek new experiences as part of acquiring 
independence from their parents. Experimenting with substances (e.g. cigarettes, alcohol) 
is an example of such an experience. Some experimentation is considered normal. 
However, as argued earlier experimenting with substances can lead to Substance Use 
Disorders. Fortunately, only a minority of youth who experiment with substances develop 
a substance-related disorder (Spear, 2000). Secondly, the developing brain has an 
immature inhibitory mechanism. The continued development of the PFC means a mature 
level of judgment has not been reached. As a result, adolescents’ combination of 
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immature judgement and motivation to seek new experiences means they are more likely 
than other age groups to experiment with substances (Chambers et al., 2003). 
 As discussed earlier, drugs exert their actions via the DA reward pathway. This 
pathway includes the NA and the PFC which both undergo development during the 
periadolescent period. Interference with the brain’s normal development can lead to 
regionally specific deficits (Andersen & Navalta, 2004). For example, an immature PFC 
can result in poor judgment and difficulty processing complex information (Cassey et al., 
2000). Therefore, drugs which interfere with brain maturation can have specific 
consequences latter in life. In addition, deficits could affect one sex more than the other 
due to differing rates of brain maturation in males and females. The following sub-section 
will discuss a theoretical approach to this phenomenon. 
 
1.3.1 Neuronal Imprinting Theory 
Neuronal imprinting occurs when the effects of drug exposure outlast the drug 
itself (Andersen & Navalta, 2004). Specifically, drug exposure during adolescence 
modifies the maturation of brain regions where the substance is active (Andersen, 2003). 
The brain alteration demonstrated by adolescents is different from what would be 
experienced by adults as studies of both humans and animals suggest the adolescent brain 
is more sensitive than the adult brain to the longer lasting effects of substances (Smith, 
2003). 
 Drugs such as neuroleptics, marijuana, nicotine, alcohol, and stimulants have 
provided evidence for neuronal imprinting (see Andersen, 2003 for a review). For 
example, Graham & Diaz-Granados (2006) repeatedly administered alcohol to adult and 
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adolescent rodents. The subjects’ conditioned taste aversion to the drug was tested six 
weeks after the final administration. Adolescent mice showed an attenuated response to 
alcohol taste aversion whereas adults did not. This finding suggests exposure to alcohol 
on the developing brain can lead to long-term changes in the aversive properties of 
alcohol.  
Given there is evidence that exposure to drugs during adolescence can lead to 
behavioural changes in adulthood, it is likely adolescent exposure to BZP alone and/or 
alcohol will have consequences in adulthood. Any differences observed during adulthood 
would be consistent with the neuronal imprinting account of adolescent drug exposure. 
In summary, adolescence represents a vulnerable period for the enduring effects 
of drugs. Substance experimentation is most likely to occur during adolescence and early 
adulthood. To complicate matters, the brain is very sensitive to the effects of drugs during 
this period. Given adolescents are susceptible to the long-lasting effects of substances and 
are most likely to experiment with them they deserve special attention. Therefore, 
researchers should pay particular attention to the periadolescent period when studying the 
developmental effects of drugs.  
 
1.4 Methylenedioxymethamphetamine (Ecstasy) 
 Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) is an illicit amphetamine 
derivative which is popular with young people (Cassel et al., 2005; Wilkins, Girling, 
Sweetsur, & Butler, 2005). In humans, MDMA acts as a central nervous system (CNS) 
stimulant. It produces euphoria, enhanced well-being, and cognitive alterations (Peroutka, 
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Newman, & Harris, 1988). Understanding the mechanisms of action of MDMA is 
important as they are similar to those of BZP.  
 MDMA causes a release of 5-HT and DA in the brain via carrier release and/or 
reuptake inhibition of these neurotransmitters (Cassel et al., 2005; Fone, Beckett, 
Topham, Swettenham, Ball, & Maddocks, 2002). MDMA can elicit potentially fatal 
hyperthermia in rodents, primates, and humans. Chronic exposure results in depletion of 
5-HT in the cortex, hippocampus, and striatum as these structures are highly sensitive to 
MDMA (Cassel et al., 2005, Piper, 2007). Finally, using MDMA can result in 5-HT 
toxicity. 5-HT toxicity (also know as the serotonin syndrome) is caused by excessive 5-
HT release. Symptoms include (but are not limited to) confusion, hallucinations, coma, 
shivering, diarrhoea and seizures. 5-HT toxicity is potentially life threatening if left 
untreated (Piper, 2007; Clemens, Cornish, Hunt, & McGregor, 2007). These symptoms 
are a result of acute MDMA exposure. However, there are possible longer-term 
consequences of ecstasy use. 
 Some research suggests MDMA exposure can increase the likelihood of 
developing depression. The rationale for this statement comes from findings of drug 
treatments which decrease depression by increasing 5-HT levels. Given MDMA depletes 
5-HT it is possible it will have the opposite effect by increasing depression amongst users 
(Piper, 2007). Although reports of consistent major depression following MDMA use are 
mixed, one longitudinal study of 14 – 24 year olds has found evidence of persistent mild 
depression following MDMA exposure (Lieb, Schuetz, Pfister, von Sydow, & Wittchen, 
2002). This finding suggests MDMA use can have consequences which outlast the acute 
effects of the substance. 
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Research on adolescent MDMA exposure has found longer-term behavioural 
outcomes. For example, Fone and colleagues (2002) administered adolescent rats either 
MDMA or saline. When tested during adulthood up to 29 days after the last injection they 
found significant attenuation of social interactions and enhanced sub-threshold 
conditioned place preference (CPP) to cocaine compared to saline controls. A major 
strength of this study was the use of a relatively low dose of MDMA that resulted in adult 
behavioural differences in the absence of neurotoxicity. This suggests that even exposure 
of the developing brain to low doses of MDMA can have negative behavioural outcomes 
in later life. 
 In a later study, Achat-Mendes, Anderson, and Itzhak (2003) exposed adolescent 
mice to MDMA to assess its effects on cocaine-induced reward in adulthood. During 
adulthood, MDMA and saline subjects exhibited similar levels of CPP to cocaine. 
However, two weeks following extinction of CPP and withdrawal from cocaine, a small 
priming dose of cocaine reinstated CPP at a significantly higher level in MDMA-treated 
mice compared with controls. The authors concluded that adolescent exposure to MDMA 
induced long-lasting neuronal adaptations which sensitized subjects to the rewarding 
properties of cocaine. This finding further supported adolescents being particularly 
vulnerable to the long-lasting effects of MDMA. 
 Overall, there is a relative lack of research into the long-term effects of 
periadolescent exposure to MDMA. However, results to date suggest that such exposure 
can have negative behavioural outcomes later in life. 
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1.5 1-Benzylpiperazine 
 Party pills, containing the psychoactive ingredient 1-benzylpiperazine (BZP), are 
regularly taken by young New Zealander’s for their subjective psychoactive effects 
(Johnstone et al., 2007). BZP acts on the CNS producing feelings of euphoria, 
wakefulness, and increased vigilance. The average duration of these effects is 6 – 8 hours 
(EACD, 2004). BZP alone and combined with other piperazine derivatives such as 1-(3-
trifluromethylphenyl)piperazine (TFMPP), produces effects very similar to MDMA 
(Baumann, Clark, Budzynski, Partilla, Blough, & Rothman, 2005; de Boer et al., 2001; 
Fantegrossi, Winger, Woods, Woolverton, & Coop, 2005). For this reason, BZP 
containing pills have become popular within the dance party scene. They are regarded as 
a safer legal alternative to drugs such as MDMA. However, little is known about their 
longer-term effects (EACD, 2004; Johnstone et al., 2007). Party pills are readily available 
to those 18 years or older from specialty stores such as Cosmic Corner and Herbal 
Heaven. In 2007, an estimated five million party pills were sold in New Zealand (Gee & 
Fountain, 2007). The combination of BZP’s ready availability with the impression it is 
safe, means more research is required to clarify the possible long-term effects of 
adolescent exposure to BZP. 
 Interestingly, there is a popular view that BZP was originally developed as a 
potential antihelminthic agent (a treatment for internal parasites) for cattle (EACD, 2004; 
Fantegrossi et al., 2005). BZP’s parent compound piperazine was developed for this use, 
but BZP was not (EMCDDA, 2008). Therefore, the idea that BZP is a cattle drench is 
inaccurate. In 1971, BZP’s potential as an antidepressant was evaluated as it was found in 
rats to reverse the sedative effects of tetrabenazine, a drug used to treat hyperkinetic 
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movement disorders (unpublished work by Miller, Green, & Young, 1971, cited in 
Fantegrossi et al., 2005). However, it was never marketed as an antidepressant possibly 
because of its similarity to the amphetamines (as will be discussed later).  
 In New Zealand, prior to 2005 BZP was available for purchase by anyone 
regardless of age. Currently BZP is a restricted substance in New Zealand. Its sale is 
limited to those 18 years of age or over. In addition, the advertisement of piperazine 
containing party pills is prohibited from major media sources such as television, radio, 
and newspapers (Wilkins et al., 2006). A ban outlawing the sale, possession, distribution, 
importation, and manufacture of BZP and other piperazine’s (e.g. TFMPP) was due to 
take effect in December 2007. However, delays with Parliament passing the bill meant 
this law did not take effect until April 1st 2008. Persons possessing party pills now have 
six months from this date to use or dispose of their supplies. 
 Staff members from Christchurch Hospital’s emergency department (ED) have 
reported the effects of BZP from 61 people who presented themselves to the ED. Gee, 
Richardson, Woltersdorf, & Moore (2005) found mild symptoms included insomnia, 
anxiety, nausea, and palpitations. Serious cases included toxic seizures, epileptic attacks 
and severe respiratory and metabolic acidosis. Two cases were admitted to the hospital’s 
intensive care unit. It was concluded that BZP products had a narrow safety margin 
possibly due to intrinsic pharmacodynamic properties, dosage variability, and/or genetic 
factors. This study provided seemingly persuasive evidence for the negative effects of 
BZP. However, the conclusions made cannot be held with certainty. Due to the nature of 
the study, it was not possible to control for extraneous factors such as poly drug use and 
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doses taken. Therefore, experimental studies are needed to establish cause and effect 
relationships thereby confirming any observations made in clinical settings.  
 The principle mechanisms of action of BZP are similar to those of the 
amphetamines (Aitchison & Hughes, 2006; Baumann et al., 2005; Hashimoto, Maeda, & 
Goromaru, 1992). In vivo microdialysis studies have shown BZP administration causes a 
parallel rise in extracelluar DA and 5-HT dialystate levels in the NA with the 
dopaminergic effect predominant (Baumann et al., 2005). In vitro studies have shown 
that blockade of DAT reuptake attenuated BZP’s release of the DAT substrate [3H]MPP. 
This suggests BZP’s release of DA is mediated via the DAT (Baumann et al., 2005). 
Interestingly, BZP had no in vitro effect on 5-HT release from the synaptosomes 
(Baumann et al., 2005). The inconsistencies between in vivo and in vitro studies are 
similar to early observations of methamphetamine (Baumann et al., 2002). This finding 
may be a sign of in vivo interaction between DA and 5-HT release. Essentially, BZP’s 
facilitation of DA and 5-HT is shared with MDMA. Therefore, there is little to 
distinguish the mechanisms of action of BZP from those of the amphetamines (Baumann 
et al., 2005; Johnstone et al., 2007; Yarosh, Katz, Coop, & Fantegrossi, 2007). 
 Importantly, BZP has abuse potential at levels similar to the amphetamines. Like 
the amphetamines, BZP has been shown to induce conditioned place preferences, to elicit 
self-administration of the drug, and to produce sensitization and cross sensitization to 
other stimulants (as will be illustrated below). 
Studies of the rewarding properties of BZP have shown it will induce conditioned 
place preferences in rats (Meririnne, Kajos, Kankaanpaa, & Seppala, 2006). This place 
preference was attenuated by pharmacological blockade of DA D1-like receptors and 5-
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HT3 receptors thereby suggesting that BZP has rewarding properties mediated via the 
dopaminergic and serotonergic systems. As noted earlier, these systems are involved in 
the rewarding properties of MDMA (Baumann et al., 2005; Glennon, Young, Rosecrans, 
& Anderson, 1982). 
Fantegrossi et al. (2005) investigated the reinforcing effects of BZP and TFMPP 
in rhesus monkeys previously trained to self-administer cocaine and found that BZP acted 
as a reliable reinforcer whereas TFMPP did not. The subjects self-administered BZP at 
levels equal to or higher than what they did for cocaine. This finding suggested that BZP 
has abuse potential similar to that of amphetamine, whereas TFMPP does not. In 
addition, Campbell, Cline, Evans, Lloyd, and Peck (1973) reported a group of 
amphetamine addicts who liked the effects of both 10 mg dexamphetamine and 100 mg 
BZP. From subjective reports of the drugs’ effects, participants were unable to accurately 
discriminate between the two but preferred the effects of BZP. The difference in dosage 
used suggests BZP can produce an amphetamine-type response by taking ten times the 
recommended dose 
BZP also has the potential to act as a gateway drug for other stimulants such as 
methamphetamine. In a recent study, repeated exposure to BZP produced behavioural 
sensitization and cross-sensitization to methamphetamine (Brennan, Johnstone, 
Fitzmaurice, Lea, & Schenk, 2007). This finding suggests that BZP can act as a gateway 
for amphetamine-type drugs possibly because of dopaminergic neuroadaptations which 
would sensitize users to other stimulants of abuse. In addition, in their survey, Wilkins et 
al. (2006) found 13.5% of respondents reported starting using party pills before they 
mainly used other illegal drugs. Together these findings suggest that BZP has the 
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potential to act as a gateway for other illicit drugs. Therefore, research into such gateway 
effects is warranted. 
To date research on the longer-term outcomes of repeated adolescent exposure to 
BZP is very limited. However, local research by Aitchison & Hughes (2006) has 
provided some preliminary results of interest. In their study, adolescent rats were 
administered 10 mg/kg BZP daily for ten days. When tested during adulthood 17 days 
later, behavioural differences were observed between BZP treated rats and saline 
controls. Specifically, they found BZP-treated rats displayed heightened anxiety during 
adulthood. Interestingly, neuronal imprinting was demonstrated as the effects of exposure 
to the BZP outlasted the effects of the drug itself. This was possibly due to interference 
with the maturation of anxiety-associated forebrain mechanisms operated by 5-HT. 
In summary, BZP is a substance regularly consumed by New Zealand young 
people. This is a major societal concern as there is little knowledge about the long-term 
outcomes of BZP exposure. BZP has the potential to be abused at levels similarly 
observed by the amphetamines. Currently, there is little to distinguish the mechanisms of 
action of BZP from MDMA. Additionally, BZP has the potential to act as a gateway drug 
to harder illicit substances. Therefore, research which elucidates the effects of repeated 
adolescent exposure to BZP is required. 
 
1.6 Ethanol 
 Ethanol (drinking alcohol) is one of the most widely used psychoactive 
substances in the world. It is a recreational substance taken for its depressant effects on 
the CNS. Ethanol is rarely consumed in its pure form. Instead, it is mixed with other 
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liquids to produce varying concentrations e.g. 12% in wine, 4% in beer (Julien, 2001). In 
New Zealand, alcohol containing beverages are available for purchase by those aged 18 
years or older. Those under 18 can drink at a private home or function, in supervised 
areas of pubs or restaurants, or in a public place when their parent or legal guardian 
supervises them (ALAC, 2008). 
 At moderate to high doses ethanol impairs motor coordination and cognitive 
abilities such as the speed of information processing and memory recall (Sircar & Sircar, 
2006). At moderate doses the effects of ethanol consumption can result in pleasurable 
feelings (positive reinforcement) and/or anxiolysis and stress reduction (negative 
reinforcement). These effects can serve as a reinforcing mechanism for people who 
consume alcohol (Eckardt et al., 1998). 
 Ethanol’s mechanisms of action are complex and varied. Moderate consumption 
of ethanol selectively affects the function of γ-aminobutyric acid via type A receptors 
(GABAA), glutamatergic, serotonergic, dopaminergic, cholinergic, and opioid neuronal 
systems (Cami & Farre, 2003; Thanos, Dimitrakakis, Rice, Gifford, & Volkow, 2005). It 
affects the brain by either directly acting on these systems or through interactions 
between them (Sircar & Sircar, 2006). The pharmacological effect of ethanol is the sum 
of its interactions with these systems. For example, some ethanol doses produce sedation 
whereas others are stimulatory. Therefore, the specific behavioural effect observed 
depends on the dose and how it interacts with these systems (Eckardt, et al., 1998). 
 The reinforcing properties of ethanol have been assessed using conditioned place 
preference (CPP) tests. This test involves training an animal to associate a drug with a 
particular environment. In the absence of the substance, reinforced animals will prefer the 
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environment associated with drug administration. Several studies have found evidence of 
ethanol CPP in the rat (e.g. Bechtholt & Cunningham, 2005; Cunningham, Niehus, 
Malott, & Prather, 1992). These findings confirm that ethanol has abuse potential. 
 Currently there is little research on the longer-term outcomes of adolescent 
exposure to ethanol. Research conducted by DeBellis et al., (2000) measured the 
hippocampal volumes of alcohol-dependent adolescents. Hippocampal volumes were 
significantly smaller in adolescents with alcohol use problems compared to controls. In 
addition, Spear (2002) suggests that females are more sensitive to the effects of ethanol 
than males. This could be partly due to females having shorter drinking histories than 
males (see Spear, 2002 for a brief review). In comparison to human studies, some animal 
studies have shed light on adolescent exposure to ethanol. 
 As mentioned earlier, adolescent exposure to ethanol leads to long-term changes 
in its aversive properties in rats (Graham & Diaz-Granados, 2006). Additionally, 
adolescent exposure has led to long-term impairment of spatial memory and learning (see 
Sicar & Sicar, 2005). This finding suggested that ethanol led to cognitive dysfunction of 
the developing brain. Further findings by Pascula, Blanco, Cauli, Minarro, & Guerri 
(2007) have supported this conclusion. In their study, they intermittently exposed 
adolescent rats to ethanol. When tested during adulthood they found impaired 
performance on cognitive tasks such as object recognition and discrimination learning. 
The impaired performance was most likely due to increased cell death in the neocortex, 
hippocampus, and cerebellum. Together these findings suggest adolescent exposure to 
ethanol can lead to long-term changes in behaviour and cognitive performance. 
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Therefore, more research into the longer-term behavioural and cognitive consequences of 
adolescent exposure to ethanol is required. 
 
1.7 Combined Exposure to MDMA and Ethanol 
 As discussed earlier there is little to distinguish BZP’s neurochemical and 
behavioural effects from MDMA. Both substances have demonstrated long-term 
behavioural outcomes following adolescent exposure. In addition, ethanol has also shown 
long-term detrimental effects when administered during adolescence. Given BZP and 
MDMA are similar in their effects if combined exposure to MDMA and ethanol has long-
term consequences it is likely combined exposure to BZP and ethanol will have long-
term effects. 
 To date there is only one study which addresses the long-term effects of combined 
exposure to MDMA and ethanol in experimental animals. In their study, Cassel et al. 
(2005) administered rats MDMA and/or ethanol or saline over four consecutive days. 
Starting four days after the last injection they monitored the animals’ behaviour and 
neurochemistry. In the long-term the combined exposure effects on behaviour were 
similar to those observed by MDMA alone. However, neuropharmacological results 
found combined exposure had specific long-term effects on presynaptic modulation of 5-
HT release in the hippocampus. They concluded that the psychological problems reported 
by MDMA users who concurrently drink alcohol are possibly not an exclusive result of 
MDMA alone. Because combined exposure to MDMA and ethanol resulted in specific 
long-term consequences, combined exposure to BZP and ethanol might also be expected 
to have long-term consequences. 
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1.8 The Present Study 
 The present study investigated the long-term behavioural effects of adolescent 
exposure to BZP and ethanol alone and in combination. On post natal days (PND) 41 – 
50, male and female rats were treated daily with BZP (10 mg/kg) and/or ethanol (2g/kg) 
or saline vehicle. Subjects were tested during early adulthood (PND 78 – 81) and again 
during mid-adulthood (PND 117 – 120) in a Y maze, light/dark box, and an open field. 
Differences in behaviour at each testing age were examined to assess possible additional 
deterioration from early to mid-adulthood. Sex differences in behaviour were also 
recorded because of sex differences in brain maturation (Andersen, 2003). Given males 
and females brains develop differently, exposure to these substances is likely to affect the 
two sexes differently in the long-term. 
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2.0 Aims and Hypotheses 
The aim of research described in this thesis was to provide an original 
contribution the scientific literature regarding the long-term effects of adolescent 
exposure to BZP and ethanol both alone and in combination. To date there has been little 
research into the long-term effects of adolescent exposure to these substances alone. But 
more importantly, there has been no research at all into the effects of adolescent exposure 
to these drugs when administered in combination. Because of the lack of literature on the 
combined effects of these substances, it was not possible to make any specific 
predictions. However, it was not felt unreasonable to expect there might be similar 
outcomes to those observed with combinations of ethanol and MDMA discussed above 
(Cassel et al., 2005). 
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3.0 Method 
 
3.1 Subjects 
 
The subjects were 40 male and 40 female hooded rats from the Animal Facility, 
Department of Psychology, University of Canterbury, New Zealand. On post natal day 
(PND) 30, rats were weaned and caged in 475 x 280 x 230 mm plastic cages in small 
groups (2-4) of the same sex for the period of the experiment. The animals were housed 
in a humidity-controlled (48% ± 10%) environment on a 12 hr light/dark cycle (lights on 
at 0800). The ambient temperature was 22˚C (± 2˚C). All rats had free access to food  and 
water for the duration of the study. The total number of subjects and all procedures used 
were approved by the University of Canterbury Animal Ethics Committee (see Appendix 
A).  
On PND 40, the rats were randomly assigned to four experimental conditions. 
Each group had 10 males and 10 females. From PND 41-50 subjects experienced daily 
exposure to either 1-Benzylpiperazine (BZP), Ethanol (EtOH), BZP + EtOH, and/or 
saline. All doses were freshly prepared and administered during the afternoon of the 
animal’s normal light/dark cycle. The age of drug exposure was selected to represent the 
comparative human periadolescent stage of neurodevelopment in rats (Andersen, 2003). 
The rats were behaviourally tested on measures of timidity, anxiety, and general activity 
during early adulthood (PND 78 - 81) and mid adulthood (PND 117 – 120). Testing four 
weeks after drug administration permits us to examine the longer term consequences of 
adolescent exposure to these drugs. The chosen testing periods allow the rats to reach 
adulthood. Any behavioural differences observed during adulthood are therefore not 
ascribable to the acute effects of the drugs (Andersen & Navalta, 2004).  
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3.2 Drugs and Rationale for Doses 
1-Benzylpiperazine was purchased from ABCR Gmbh & Co (Karlsruhue, 
Germany). Ethanol was purchased from BioLab (Auckland, New Zealand). BZP and 
EtOH were mixed with 0.9% isotonic saline to produce solutions of 10 mg/kg BZP and 
2g/kg EtOH. Solutions were administered in a volume of 1 ml/kg. During adolescence 
(PND 41 to PND 50), all rats received daily exposure to the drugs and/or saline via 
intraperitoneal injection (i.p.) in a volume of 1ml/kg. BZP animals received an injection 
of 10 mg/kg BZP and one of saline. Alcohol subjects were administered 2g/kg EtOH and 
saline. The combined group received 10mg/kg BZP and 2g/kg EtOH daily. Finally, 
control rats were administered two injections of 1 ml/kg saline (Table 1 shows each 
animal’s treatment regime and total exposure to BZP and EtOH). Two injections were 
required to control for the combined groups dual drug exposure. All animals received 
their two injections within five minutes of each other. The order of drug/saline 
presentation was counterbalanced so for drug-exposed animals their respective drug/s 
was administered both first and second on an equal number of treatment days. 
Intraperitoneal administration was the preferred method of delivery for its ease of use and 
accurate control of the quantity of drug administered. Body weights were recorded on 
each treatment day and doses adjusted accordingly.  
 BZP has approximately a tenth the potency of methamphetamine (Campbell, 
Cline, Evans, Lloyd, & Peck, 1973). For this reason, doses of 10 mg/kg were chosen as 
this is ten times the dose of methamphetamine shown to have mild stimulant effects on 
rats (Hughes & Greig, 1976). In addition, similar past research has used a 10 mg/kg dose 
(Aitchison & Hughes, 2006). For EtOH, a dose of 2 g/kg was chosen because this (or 
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close to) has been used in investigations of the long-term effects of adolescent exposure 
to alcohol in rats (Abreu-Villaca, Medeiros, Lima, Faria, Filgueiras, & Manhaes, 2007; 
Graham & Diaz-Granados, 2006; Sicar & Sircar, 2006).   
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Group 
Days of 
BZP 
exposure 
Days of 
EtOH 
exposure 1 2 3 4 5 6 7 8 9 10 
Total BZP 
exposure 
Total EtOH 
exposure 
Control  
(Males, 10) 0 0 S+S S+S S+S S+S S+S S+S S+S S+S S+S S+S 0 mg/kg 0 g/kg 
Control 
(Females, 10) 0 0 S+S S+S S+S S+S S+S S+S S+S S+S S+S S+S 0 mg/kg 0 g/kg 
BZP 
 (Males, 10) 10 0 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 100 mg/kg 0 g/kg 
BZP 
 (Females, 10) 10 0 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 
BZP 
(10) + 
S 100 mg/kg 0 g/kg 
Alcohol 
(Males, 10) 0 10 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 0 mg/kg 20 g/kg 
Alcohol 
(Females, 10) 0 10 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 
EtOH 
(2) + 
S 0 mg/kg 20 g/kg 
Combined 
(Males, 10) 10 10 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 100 mg/kg 20 g/kg 
Combined 
(Females, 10) 10 10 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 
BZP 
(10) + 
EtOH 
(2) 100 mg/kg 20 g/kg 
Table 1. 
Days of treatment with BZP (mg/kg), EtOH (g/kg) and Saline (S) from post natal day 41 for 40 male and 40 female rats.  
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3.3 Apparatus and Behavioural Measures  
In this study, three acknowledged tests of anxiety-like behaviour were used: 
responsiveness to change in a Y maze, an emergence test, and behaviour in an open field. 
Each of these tests were simple to use and did not require prior training of the animals or 
any form of deprivation or shock. In the Y maze, a more anxious rat will enter the 
changed arm less often, and spend less time in it than a less anxious animal (Atchison & 
Hughes, 2006). In the emergence test, a more anxious animal will take longer to emerge 
from the dark into the light than a less anxious animal (Hascoet, Bourin & Dhonnchadha, 
2000). Finally, in the open field, a more anxious animal will display less rearing 
behaviour, occupy the centre squares less and the corner squares more often, will 
ambulate less and groom more often, and defecate more often than a less anxious animal 
(Prut & Belzung, 2003; Walsh & Cummins, 1976).    
The experimental room was 22˚C ±2˚C, with humidity control 48% ±10% and 
dim lighting (44 lux). All testing took place between 1000 and 1900 hrs during the light 
phase of the animals’ normal light/dark cycle. At each of the four-day testing phases, all 
animals were tested twice in the Y maze and once each in the open field and the 
light/dark emergence box. Each of the animals completed only one test a day. To control 
for habituation effects in the Y maze, the order of testing was arranged to ensure there 
were at least two days between each of these experiences. Every possible order which 
satisfied this requirement was determined, and each order was administered to an equal 
number of subjects at both testing phases. Averages of the two Y maze trials at each 
testing phase were calculated.  
 
 
 32
3.3.1 Responsiveness to Brightness Change in the Y-Maze 
The Y maze exploits rat’s tendency to explore novel areas. An anxious animal 
will explore the novel areas of the Y maze to a lesser extent than normal animals 
(Atchison & Hughes, 2006; Hughes, 2001; Hughes & Neeson, 2003).  
The wooden apparatus sat on a 700-mm-high table and was illuminated overhead 
by dim (44 lux) fluorescent lighting 1, 390 mm above the maze. The arms of the maze 
were 45 cm long with a 120˚ angle between them. The stem of the Y was 30 cm long 
with a wooden barrier inserted to give a shorter stem of 15 cm. Both the stem and arms 
were 10 cm wide and 14 cm high. One arm contained a black and the other contained a 
white painted metal insert which occupied the width, height, and 40 cm of the length of 
the arm. A clear Perspex lid covered the entire apparatus.   
In the Y maze each animal experienced a pair of acquisition and retention trials. 
Individual animals were initially placed in the 15 cm stem and allowed to freely roam the 
maze for six minutes (acquisition trial). During the acquisition trial, one arm was black 
and the other white. After this trial the rat was returned to its normal cage. Immediately 
the inserts were replaced with two clean black inserts and the entire apparatus washed 
and disinfected with a 20% Paraquat blue solution. Rats were returned to the stem of the 
maze and allowed to freely roam for three minutes (retention trial). For the retention trial, 
one arm had been changed from white to black (novel) while the other remained black 
(familiar).    
Timing for the retention trial began when the subject fully entered (all four paws) 
an arm. For exactly three minutes, the experimenter recorded via keyboard and 
appropriate PC software, (1) the percentage of entries of the novel arm, (2) the percentage 
of time spent in the novel arm, (3) the total entries of both arms, and (4) the total time 
spent in both arms.  
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Subjects were tested in the Y maze twice at each testing phase with the novel arm 
randomly appearing left on one trial and right on the other for each subject. The two trials 
at each testing phase were averaged to represent a subject’s score for this measure.   
 
3.3.2 Light/dark Box Emergence Test  
The animals were exposed to the light/dark emergence box once at each testing 
phase. This paradigm takes advantage of rodents’ innate aversion to brightly illuminated 
areas. By applying mild stressors (in this case a novel environment and bright light), a 
natural conflict occurs between the spontaneous tendency to explore and the initial 
tendency to avoid bright light (Hascöet et al., 2000). One third of the apparatus consisted 
of a 200 x 150 x 200-mm high darkened start box (painted black on the inside) which 
opened into an illuminated arena via a sliding door. The illuminated arena comprised two 
thirds of the apparatus and was 500 x 400 x 200-mm high. The start box and the walls of 
the arena were constructed from wood. The roof was made of fine wire mesh and the 
floor of the arena constructed from translucent Perspex. The floor of the arena was 
illuminated from underneath by two 16-lux florescent tubes. The light intensity was 80 
lux in the centre of the arena and 172 lux on the floor. The centre measurement was taken 
100 mm above the centre of the floor. 
Each rat was placed in the darkened start box for 60 seconds before the sliding 
door to the arena was opened. By means of a hand-held stopwatch, the time it took to 
fully emerge (all four paws) from the dark into the light was recorded. If a subject did not 
emerge within five minutes, the trial was terminated and the rat assigned a score of 300 
seconds. The apparatus was washed and disinfected with 20% Paraquat blue between 
subjects.         
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3.3.3 General Activity in the Open-Field 
The open field measures rats’ anxiety generated by removing them from their 
social group and exposing them to a novel environment (Prut & Belzung, 2003; Walsh & 
Cummins, 1976). The plastic open-field was 600 x 600 x 305 mm high and placed on a 
700 mm high table. The walls comprised clear Perspex to allow easy observation of each 
subject’s behaviour. The floor consisted of black Perspex divided into a numbered 4 x 4 
grid of 16 equal sized (150 x 150 mm) squares. Four squares were in the centre and 
twelve occupied the periphery of the field. Dim (44 lux) fluorescent lighting illuminated 
the apparatus 1,225 mm overhead.  
A time-sampling procedure was used to measure the animals’ behaviour. 
Individual rats were placed in the centre of the open-field and after a six second delay, 
time-sampling of their behaviour began. This consisted of recording their behaviour 
every three seconds for exactly five minutes. The time samples were determined by 
means of a 3-second audio “beeper” delivered to the experimenter’s ear via headphones. 
At each interval the experimenter recorded each rat’s location and whether it was rearing 
or grooming. Location was determined by the position of the rat’s rear paws. If they were 
located in two different squares, a half score was assigned to each position. Rearing 
occurred when the animal was on its hind haunches with both front paws off the floor, 
either unsupported or supported by a wall. Grooming was defined as any nibbling, 
licking, or scratching of its body, and was preferentially recorded over rearing if the 
animal needed to rear to groom parts of its body. In addition, ambulation (transitions) was 
measured by counting the total occurrences the subject had been observed to be in a 
different square from its previous location within the field.     
For each rat the dependent variables for this test were (1) the total rearing 
occurrences observed, (2) the total grooming occurrences observed, (3) total centre 
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occupancy observed, (4) total corner occupancy observed, (5) total transitions, and (6) 
total faecal boluses deposited. All animals were tested once in the open field at each 
testing phase. After each test the apparatus was washed and disinfected with 20% 
Paraquat blue.  
A possible confounding variable of behavioural sampling is experimenter error 
i.e., observations of the behaviour emitted and when it was emitted could be inaccurate. 
Therefore, to rule out this source of error, a post hoc inter-observer reliability study was 
performed (see below).    
 
3.4 Inter-observer Reliability Study  
This study was designed to assess the possible presence of experimenter error 
during observations of animals in the open field. To achieve this, two additional 
observers independently rated the animals’ behaviour.   
 
3.4.1 Method 
The subjects were four male and four female hooded rats from the saline 
treatment group who had completed all of the experimental test phases. The apparatus 
and procedure were the same as outlined above with the exception of two additional 
observers who independently rated the animal’s behaviour. All three observers received 
their 3-second tones from the same audio beeper via means of multiple headphones and a 
multi-plug. This ensured the time sampling interval was exactly the same for each 
observer. Prior to commencement the additional observers were told how to code the 
responses. They were given practice trials to ensure their competency with the procedure. 
The animals in the practice trials were different from the eight animals used in the control 
study.  
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Each animal was tested once for five minutes. All dependent variables were the 
same as previously except faecal boluses were not counted. The apparatus was washed 
and disinfected with 20% Paraquat blue after each subject. The experimenter coded all 
data sheets and calculated the overall inter-observer reliability.  
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4.0 Statistical Analyses 
All raw data were analysed via the statistical programme Statistica 8.0. Each 
measure was treated to a separate 4 (treatment group) x 2 (sex) x 2 (age) factorial 
repeated measures ANOVA. Post hoc Tukey tests were carried out when a main effect or 
interaction was significant (p<.05). Differences in behaviour at each testing age were 
examined to observe any additional deterioration from early to mid-adulthood. Sex 
differences in behaviour were tested for due to sex differences in brain maturation 
(Andersen, 2003). Given males and females brains develop differently, exposure to these 
substances is likely to affect the two sexes differently in the long-term. 
For the inter-observer study, the Kendall Coefficient of Concordance (W) was 
calculated to assess the degree of agreement between observers.  
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5.0 Results 
5.1 Open-Field Results 
In the open field, each animal was tested once at each testing age. For main 
effects of treatment and sex, averages of both trials were used in the analyses. For the 
main effect of age, averages of each individual trial were used. The results are presented 
in Table 2. 
Table 2. 
Means (standard deviations) for transitions, corner occupancy, centre occupancy, 
rearing, grooming, and total defecations for saline (n=20), BZP (n=20), ethanol (n=20), 
and combined (n=20) treatment groups for male (n=40) and female (n=40) rats at early 
(n=80) and mid (n=80) adulthood, and results of F tests.  
Treatment group Saline BZP Ethanol Combined F P 
     (3, 72)   
 
 
Transitions 53.13(16.15) 53.50(12.43) 51.23(12.82) 54.80(13.03) 0.44 >.7a 
Corner Occupancy 40.34(14.78) 38.18(8.77) 42.53(10.91) 42.86(11.08) 1.17 >.3 
Centre Occupancy 14.63(8.30) 14.84(6.97) 13.00(6.73) 12.09(6.28) 1.14 >.3 
Rearing 25.40(9.19) 26.05(8.16) 26.08(9.08) 24.58(7.26) 0.27 >.8 
Grooming 2.03(2.85) 1.88(1.99) 2.23(1.79) 1.95(2.14) 0.14 >.9 
Defecation 3.60(2.50) 3.24(2.45) 2.33(2.44) 2.88(2.72) 1.40 >.2 
 
Sex Male Female F P 
 (n=40) (n=40) (1, 72) 
 
 
Transitions 48.78(14.18) 57.58(11.53) 16.16 <.01a 
Corner Occupancy 41.74(12.98) 40.21(10.14) 0.57 >.4 
Centre Occupancy 14.38(7.73) 12.89(6.46) 1.45 >.2 
Rearing 23.19(8.06) 27.86(8.13) 11.54 <.01 
Grooming 1.75(1.58) 2.29(2.69) 1.74 >.1 
Defecation 2.56(2.46) 3.49(2.59) 4.13 <.05 
 
Age Early adulthood  Mid adulthood F P 
     (1, 72) 
 
 
Transitions 55.34(11.78) 51.01(15.00) 6.43 <.05 
Corner Occupancy 42.47(9.93) 39.48(13.02) 3.40 .069 
Centre Occupancy 14.16(7.39) 13.10(6.88) 1.17 >.2 
Rearing 25.96(7.73) 25.09(9.06) 0.79 >.3 
Grooming 2.39(2.38) 1.65(1.98) 6.36 <.05 
Defecation 3.33(2.54) 2.73(2.57) 3.38 .075 
 
a Treatment group x Sex interaction significant (F(3, 72) = 3.79, p <.05), see text and 
figures 1 and 2.  
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5.1.1 Transitions 
There was no significant treatment effect for transitions. However, there was a 
significant sex x group interaction. This was likely due to a significant difference 
between saline and ethanol for females (p <.05, see Figure 1). The male rats did not show 
any statistically significant differences (see Figure 2).  
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Figure 1. Mean transitions for female rat’s as a function of treatment. Vertical bars denote 
the 0.95 confidence interval.   
 
 For female subjects, all BZP, ethanol, and combined treatment animals made 
fewer transitions than saline controls. However, the only significant difference was 
observed between ethanol and saline. Ethanol-treated rats made significantly fewer 
transitions than saline controls.   
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Figure 2. Mean transitions for Male Rat’s as a function of treatment. Vertical bars denote 
the 0.95 confidence interval.  
 
 The difference observed for females was not evident for males. All treatment 
groups made more transitions more than saline controls, but these differences were not 
statistically significant (p=.26). Additionally, as shown in table 2 females made 
significantly more transitions than males, and all rats made significantly more transitions 
when they were younger then when older. No other interactions were statistically 
significant. 
 
 5.1.2 Corner Occupancy 
 For corner occupancy there was no significant treatment or sex effect nor were 
there any significant interactions. However, there was a suggestive effect for age 
(p=.069) suggesting that the rats may have occupied the corners of the open field more 
often when they were younger than when they were older.  
 
 
 41
 5.1.3 Centre Occupancy 
 There was no significant treatment effect for centre occupancy. In addition, there 
was no effect for sex or age nor were any interactions significant.  
 5.1.4 Rearing 
 All rats engaged in about the same amount of rearing behaviour regardless of 
treatment or age. However, female rats reared significantly more often than male rats.  
 5.1.5 Grooming  
 There were no significant treatment or sex differences for grooming nor were 
there any significant interactions. However, the rats groomed significantly more often 
when they were younger than when older.   
 5.1.6 Defecation 
 For defecation there was no significant treatment effect. However, there was a 
significant sex difference. In the open field females defecated more often than males. 
There was also a suggestive age effect (p=.075) indicating that the rats may have 
defecated more when they were younger than when older.  
 
5.2 Light/dark Box Emergence Results    
In the light/dark emergence test, each animal was tested once at each testing age. 
For main effects of treatment and sex, averages of both trials were used in the analyses. 
For the main effect of age, averages of each individual trial were used. The results are 
presented in Table 3. 
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Table 3. 
Means (standard deviations) for emergence latencies in the light dark emergence box for 
saline (n=20), BZP (n=20), ethanol (n=20), and combined (n=20) treatment groups for 
male (n=40) and female (n=40) rats at early (n=80) and mid (n=80) adulthood, and 
results of F tests.  
Treatment group Saline BZP Ethanol Combined F P 
     (3, 72) 
 
 
Emergence- 139.47(105.62) 124.71(102.60) 145.35(111.99) 142.08(114.65) 0.23 >.8 
latency (sec)  
 
 
 
Sex Male Female F P 
 (n=40) (n=40) (1, 72) 
 
 
Emergence- 151.94(109.13) 123.86(105.84) 2.13 >.1 
latency (sec)  
 
 
 
 
Age Early adulthood  Mid adulthood F P 
     (1, 72) 
 
 
Emergence- 105.53(89.25) 170.28(115.86) 23.95      <.01 
latency (sec)  
 
 
 
 As shown in Table 3, for emergence latency there was no significant effects for 
treatment or sex. However, there was a significant effect for age. The results indicated 
that the rats took approximately one minute longer to emerge from the dark into the light 
when they were older than when younger. There were no significant interactions. 
 
5.3 Y-maze results  
Each rat was tested twice in the Y maze at each testing age. An average of the two 
scores was used to represent the animals overall score for that testing age. For main 
effects of treatment and sex, averages of both trials were used in the analyses. For the 
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main effect of age, averages of each individual trial were used. The results are presented 
in Table 4. 
Table 4.  
Means (standard deviations) for time spent in and entries of both arms and the novel arm 
for saline (n=20), BZP (n=20), ethanol (n=20), and combined (n=20) treatment groups 
for male (n=40) and female (n=40) rats at early (n=80) and mid (n=80) adulthood, and 
results of F tests.  
  Treatment group Saline BZP Ethanol Combined F P 
     (3, 72) 
 
Total time (sec) 61.78(15.59) 58.71(17.25) 60.57(19.21) 57.46(15.59) 0.46 >.7 
% Novel time 56.95(13.50) 57.84(18.32) 54.43(16.72) 56.48(14.39) 0.45 >.7 
Total entries 5.58(1.71) 5.15(1.86) 5.50(1.96) 5.50(1.78) 0.67 >.5 
% Novel entries 58.10(11.69) 53.39(16.02) 57.10(14.39) 56.85(12.93) 0.80 >.4 
 
 
Sex Male Female F P 
 (n=40) (n=40) (1, 72) 
 
 
Total time (sec)  54.42(17.80) 64.84(14.24)  13.29 <.01 
% Novel time  57.01(18.42) 55.84(12.62)  0.59 >.4 
Total entries  4.71(1.72) 6.15(1.64)  21.19 <.01a 
% Novel entries  56.70(16.65) 56.02(10.38)  0.09 >.7 
 
Age Early adulthood  Mid adulthood F P 
     (1, 72) 
 
 
Total time (sec)  58.35(19.32) 60.91(14.07)  0.58 >.4 
% Novel time  55.64(17.25) 57.22(14.16)  0.07 >.7 
Total entries  5.36(2.01) 5.50(1.61)  0.61 >.4a 
% Novel entries  54.69(14.89) 58.03(12.56)  2.38 >.1 
 
 aSex x age interaction effect significant (F(1, 72) = 10.15, p<.01), see text.    
 
 5.3.1 Total Time 
 There was a significant effect for sex with females spending more time in both 
arms of the Y maze than males. No other main effects or interactions were significant. 
 
5.3.2 %Novel Time 
 For % time spent in the novel arm there were no significant main effects or 
interactions. 
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 5.3.3 Total Entries 
 There was a significant sex effect for total entries of both arms of the apparatus. 
Females entered the arms more often than males. Additionally, there was a significant sex 
x age interaction effect. This difference was most likely due to males entering the arms 
significantly more at mid adulthood (M = 5.10, SD = 1.61) than at young adulthood (M = 
4.33, SD = 1.75), F(1, 36) = 9.51, p<.01. Females entered the arms more at young 
adulthood (M = 6.40, SD = 1.72) than at mid adulthood (M = 5.90, SD = 1.30). However, 
this difference was not significant, F(1.36) = 2.17, P>.10. No other main effects or 
interactions were significant.   
 
 5.3.4 %Novel Entries 
For % entries into the novel arm there were no significant main effects or 
interactions.   
 
5.4 Inter-Observer Reliability Study 
 Overall, the inter-observer reliability for behaviour in the open-field was very 
good. The raw data presented in appendix B show little differences in ratings between the 
judges. The Kendall Coefficient of Concordance (W) was calculated to assess the degree 
of agreement between the observers. For each behaviour, W indicates the extent of 
agreement between the observers. When W equals 1.0, all observers completely agreed 
about how much of a given behaviour a subject showed relative to other animals.  
 For transitions, corner occupancy, centre occupancy, and rearing W was 0.98 in 
each case, thereby indicating a very high degree of agreement between the observers. 
Since grooming rarely occurred (see appendix B), W was not calculated for this response. 
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These results suggest that reliability of the experimenter’s observations had not been a 
major source of error during earlier open-field testing. 
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6.0 Discussion of Results 
 In this study, adolescent rats were administered BZP and/or ethanol, or saline 
vehicle. All animals received daily exposure to 10 mg/kg BZP, 2 g/kg ethanol, BZP + 
ethanol, or saline via i.p. injection during the periadolescent stage of development (PND 
41 – 50, Andersen, 2003). Following the last injection, animals were tested on three 
measures of anxiety-like behaviour during early adulthood (PND 78 – 81) and again 
during mid-adulthood (PND 117 – 120).  
  
6.1 Summary of Results 
 The results revealed a lack of behavioural differences between the drug-treated 
animals and saline controls. This means that, exposure to BZP and/or ethanol during 
adolescence did not influence the anxiety-like behaviour of the rats when they reached 
adulthood. Therefore, the expectation that there might be differences in behaviour 
between the treatment groups was not supported. The results of the three tests are 
summarized as follows. 
In the open field, there were no differences between the treatment groups on 
measures of corner occupancy, centre occupancy, rearing, grooming, and defecation. 
However, for transitions, females treated with ethanol ambulated significantly less often 
than saline females. During observations of animals in the open-field the experimenter 
could have been a source of error. The inter-observer reliability study was designed to 
exclude this possibility. This revealed a high degree of agreement between all observers 
regarding the frequencies of each response emitted by each animal. Consequently, the 
experimenter can be excluded as a significant source of error during open field 
observations. In the light/dark emergence box there was no difference in time to emerge 
from the dark into the light between the treatment groups. Finally, in the Y maze there 
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were no treatment effects on measures of time spent exploring the arms, percent time in 
the novel arm, total entries of both arms, and percent entries of the novel arm. Together, 
with the possible exception of ethanol treated females, these results suggest adolescent 
exposure to BZP and/or ethanol did not have adulthood consequences on these measures 
of anxiety-like behaviour. 
 
6.1.1 Sex Differences 
Significant sex differences were observed in both the open field and the Y maze. 
In the open field females ambulated, reared and defecated more than male rats. Open-
field studies using both adult female and male rats have found females ambulate and rear 
more than males (Andersen, 2003; Slob, Huizer, & Van der Werff Ten Bosch, 1984; 
Valle & Bols, 1976). In general, females are more active than males in the open-field. 
However, this difference is not observed until after puberty (see Slob et al., 1976). 
Interestingly, contrary to usual findings (Masur, 1972; Slob, Bogers, & Van Stolk, 1981), 
the females defecated more than males during open-field testing. This could mean that, in 
this particular study, the females were more anxious than the males. However, this is not 
likely as the difference was small and females also ambulated and reared more than 
males. Finally, males and females showed a difference in responsiveness to ethanol 
treatment. Female rats treated with ethanol ambulated less than female controls. Males 
did not show this difference. An explanation for this finding is that adult female increases 
in open-field ambulation are attributed to the organizing effects of adolescent gonadal 
steroid exposure (Slob et al., 1984). Ethanol exposure during this period could have 
interfered with this mechanism thus decreasing ethanol-exposed females’ ambulatory 
behaviour in adulthood. This finding suggests adolescent ethanol exposure might affect 
females more than males. Further research is required to substantiate this possibility. 
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In the Y maze, females made more entries of the arms and spent more time in 
them. This finding is consistent with most previous research on sex differences in Y-
maze performance (Hughes & Neeson, 2003; Palanza, 2001). Together the results from 
the open field and Y maze are consistent with the view that females show more 
exploratory activity than males (Andersen, 2003; Slob et al., 1984; Valle & Bols, 1976).  
 
6.1.2 Testing -age Differences 
Significant testing-age differences were observed in each of the tests. In the open 
field, the rats ambulated and groomed less when they were older than when younger. 
Less ambulation when older is consistent with the notion of rodent age-related 
differences in emotionality. The findings suggest that, as rats get older they increase their 
anxiety-like behaviour (Boguszewski & Zagrodzka, 2002 Miyagawa, Hasegawa, Fukuta, 
Amano, Yamada, & Nabeshima, 1998). In the open field, older rodents show less 
locomotor activity than younger animals (Boguszewski & Zagrodzka, 2002). The 
decrease in grooming behaviour is interesting and difficult to explain. One study of 
female rats also found a decrease in grooming behaviour with age (Scimonelli, Marucco, 
& Celis, 1999). The generally accepted explanation is that rodents display less activity 
with age (Miyagawa et al., 1998; Scimonelli et al., 1999). In addition to these findings, 
there were nonsignificant suggestions of less corner occupancy and defecation in older 
rats. Less corner occupancy is consistent with decreases in activity with age. Less 
defecation is harder to explain. Findings suggest rodents defecate less over successive 
exposures to the open field. This is due to less anxiety because of familiarity with the 
apparatus (Walsh & Cummins, 1976). In summary, the rats were less active in the open 
field when older than when younger. This is consistent with previous research. 
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In the light/dark emergence box, the rats took longer to emerge from the dark into 
the light when older than when younger. Hascöet et al. (2001) argued that naïve rats 
usually take longer to emerge than rats that have had previous exposure to the test. 
However, this finding is for rodents within the same developmental period. Therefore, the 
increase in emergence time with age is consistent with older rats being less active and 
more emotional (Scimonelli et al., 1999). 
In the Y maze, there was a significant sex x age interaction. Male subjects entered 
the arms more often at mid-adulthood than they did at young adulthood. This finding is 
inconsistent with rodents displaying less activity and more anxiety when older. Casual 
observations of the males’ behaviour suggested that they were more cautious about 
entering the arms when they were younger. When younger, the males tended to visually 
inspect the arms more often than females before entering them. This observation is 
supported by suggestions that female rats have superior visual exploratory capabilities 
than males (Hughes, 2001). However, the behaviour was less evident at mid-adulthood 
and may have been a result of repeated testing. At this age the rats had already been 
tested at least twice in the Y maze. The anxiety induced by the Y maze’s novel 
environment was probably reduced because of familiarity with the apparatus. In 
summary, several testing age differences were observed. However, no additional 
deterioration from early to mid-adulthood as result of adolescent treatment was evident. 
 
6.2 Methodological Strengths 
 The methodological strengths and limitations of this study need to be discussed to 
address the extent to which these findings can be generalized. The current experiment has 
several strengths and advantages. The use of rats is advantageous as they develop more 
quickly than humans do. To detect the consequences of adolescent BZP and ethanol 
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exposure on adulthood behaviour in humans would take many years. However, rats reach 
adulthood approximately two weeks after the periadolescent period (Andersen, 2003, 
Spear, 2000). This means the result of such exposure on adulthood behaviour can be 
detected much more quickly in rats than in humans. Detecting any negative outcomes in 
rats means that some understanding of the implications for humans can be acquired 
before clinical data are available. The aim of this research was to provide a longer-term 
assessment of consequences following adolescent BZP and ethanol exposure. The 28 
days between last drug treatment and first testing means any differences in behaviour 
observed would not have been a result of the acute effects of the substances.  
 Applying findings from animal studies to humans should be done with caution. 
Animal studies of long-term effects of drug exposure provide a model for the enduring 
effects of substances rather than an exact replication of the human condition (Smith, 
2003). Therefore, the strength of pre-clinical studies is to provide evidence of the effects 
of substances for use in clinical assessments (Andersen & Navalta, 2004). 
 Human users of BZP and ethanol often use other drugs (e.g. nicotine, caffeine, 
MDMA) in addition to these substances. Such poly drug use can ‘cloud’ the accuracy of 
clinical assessments and human drug research. The limitations of human drug research 
can include the non-random assignment of participants to drug conditions, the deleterious 
effects of other psychoactive substances, and the possibility that adverse effects observed 
could be a result of drug user’s susceptibility to psychopathology rather than the 
substance itself (Parrott, 2000). Therefore, the use of animals is useful for conducting 
experimental research. In this study, any differences observed (or the lack of in this case) 
is not a result of underlying psychopathology as subjects were randomly assigned to 
conditions. In addition, all subjects’ experiences were the same as they were handled, 
weighed, treated, and tested in exactly the same manner. Poly drug use was not an issue 
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as the animals were only administered the substances appropriate to their treatment 
group. Therefore, this study addresses some of the limitations commonly encountered in 
human drug research. 
 Finally, the last major strength of this research was the inter-observer reliability 
study. The result of this study excluded the experimenter as a source of error during 
open-field observations. Therefore, observational errors were probably not a major 
confounding variable. 
 The aim of this research was to provide the first model of long-term behavioural 
outcomes following repeated adolescent exposure to BZP and/or ethanol. While even 
taking account of its methodological strengths, the findings of this study were intended to 
be preliminary. It was designed to facilitate additional research in this area by providing a 
credible starting point. Consideration of the methodological limitations will hopefully 
help direct future investigations in this area. 
 
6.3 Methodological Limitations 
 During this study, several limitations became apparent. The acute effects of drug 
exposure were not measured. Casual observations of BZP’s acute effects were 
interesting. Soon after treatment with BZP or BZP + ethanol, these animals displayed 
hyperactivity and excessive grooming. Importantly, these acute effects are typical of the 
acute effects of MDMA (Vorhees, Reed, Skelton, & Williams, 2004). These effects have 
been observed in rodents and rhesus monkeys (Lile, Ross, & Nader, 2005; Vorhees et al., 
2004) Therefore, this study would have benefited from measurements of some of the 
acute effects of exposure to the substances as casual observations of BZP suggested it had 
similarities to MDMA in its behavioural effects.  
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 The second limitation which became apparent was the relatively narrow range of 
testing ages. Four days of testing at each phase of adulthood was expected to be adequate 
to detect any behavioural differences. However, the length of each of these phases is 
longer than the four days the subjects were tested. The experiment may have benefited 
from testing over the entire duration of these periods. This limitation is discussed in detail 
in the General Discussion section. 
This study would have benefited from neurochemical analysis of the rats’ brains 
but such analyses were outside the scope of this thesis. Nevertheless, if it could have been 
arranged, neurochemical analyses of the brain regions where the substances are active 
would have been informative. For example, abnormal 5-HT activity has been implicated 
in both anxiety and depression (Graeff, 2002; Piper, 2007). In comparison, DA activity 
has been implicated in motor coordination as rats administered a D1 DA receptor 
antagonist display less locomotion and rearing behaviour (Hoffman & Beninger, 1985; 
Spina, Longoni, Mulas, Chang, & Chiara, 1998). Therefore, if differences in adulthood 
neurochemistry were found this would have indicated long-term consequences following 
adolescent drug exposure. 
The use of intraperitoneal (i.p.) injection as the method of drug delivery could be 
considered a limitation. Human users of BZP and ethanol usually administer them orally. 
Rats will voluntarily take ethanol orally (e.g. Thanos et al., 2005). However, it is not 
known if this also applies to BZP. Consequently, i.p. injection was preferable as it 
ensured the subject received an accurate dose. Most importantly all animals were exposed 
to the same treatment procedures. This means the results are not attributable to 
differences in dosing procedures. 
 Finally, in the light/dark emergence test the presence of the experimenter could 
have distracted the animals. Supporters of the light/dark test argue that automated 
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versions of the apparatus are highly preferable as there is nobody present during testing 
(Bilkei-Gorzo, Gyertyan, & Levay, 1998; Hascöet et al., 2001). The use of an automated 
apparatus would have removed any extraneous influences arising from the presence of 
the investigator. However, in this study the same experimenter was present for all 
light/dark tests so that behavioural differences were at least not attributable to the 
presence of different observers. 
In summary, although this study had several limitations, none of them were 
sufficient to completely invalidate the results. Therefore, it can be reasonably concluded 
that adolescent exposure to BZP and/or ethanol did not result in observable differences in 
adulthood behaviour. However, even though this particular study did not find behavioural 
differences this does not mean that adolescent exposure to these substances definitely has 
no longer-term outcomes. The remainder of the discussion will address this possibility. 
 
6.4 Relationship to Previous Findings 
 One of the findings of the present study was that adolescent exposure to BZP 
alone did not have longer-term consequences. This was inconsistent with previous 
research.  
Atichison and Hughes (2006) daily exposed adolescent rats to 10 mg/kg BZP 
during PNDs 45 – 55 and assessed their behaviour during early adulthood (PND 72 – 95). 
All rats were observed in the Y maze (four times), open-field social interaction test 
(twice), and the light/dark emergence box (six times). In the Y maze, treated animals 
entered the novel arm less often, spent less time in it, and entered and spent less time in 
both arms than saline controls. In the open field, treated subjects ambulated and reared 
less, and engaged in fewer social interactions than controls. Finally, in the light/dark 
emergence test, animals previously treated with BZP took longer to emerge than controls. 
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Together, their findings are consistent with treated rats displaying heightened anxiety 
during adulthood. Unfortunately, comparable results were not found in this experiment. 
 There is little research which investigates the longer-term effects of adolescents 
exposed to ethanol. Thus far studies have shown adolescent rats exposed to alcohol 
develop attenuated ethanol-induced conditioned taste aversions and impaired spatial 
memory and learning when adults (Graham & Diaz-Granados, 2006; Sicar & Sircar, 
2005). In addition, adolescent but not adult ethanol exposure impaired tone conditioning 
in an auditory fear task in the long-term (Bergstrom, McDonald, & Smith, 2006). This 
finding suggests that adolescent ethanol exposure can impair adulthood fear learning. 
Each of these findings demonstrates longer-term consequences of ethanol exposure. 
However, the studies concerned did not address the consequences for anxiety-like 
behaviour. 
In their study, Salimov et al. (1996) investigated the long-term outcomes of 
adolescent ethanol exposure on anxiety-like behaviours. They repeatedly treated 
adolescent rats with ethanol and subsequently tested their behaviour during adulthood. 
Subjects were tested on measures of novelty-induced anxiety and stress as a result of 
being exposed to an inescapable situation. Interestingly, they found adolescent ethanol 
treatment reduced the anxiety associated with the novel environment and the stress 
associated with the inescapable situation (Salimov, McBride, McKinzie, Lumeng, & Li, 
1996). A comparable finding of long-term ethanol induced reduction of anxiety was not 
evident in this experiment. 
Given that the present study was the first to investigate the longer-term effects of 
combined BZP and ethanol exposure on the developing brain, no direct comparisons can 
be made. Because Cassel et al. (2005) found combined exposure to MDMA and ethanol 
during adolescence resulted in specific long-term effects on presynaptic modulation of 5-
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HT release in the hippocampus, it is possible that combined exposure to BZP and ethanol 
might have long-term effects on memory. In addition to measuring anxiety-like 
behaviour, the Y maze is useful for measuring short-term memory (Hughes & Neeson, 
2003). However, results for animals in the combined treatment group did not suggest any 
impairment of short-term memory compared to controls. This was because of the lack of 
between-groups differences in percentages of time spent in and entries of the novel arm. 
These measures are indices of spatial memory in rats (Hughes & Maginnity, 2007). In 
summary, although some earlier research has suggested that adolescent exposure to BZP 
or ethanol can have long-term consequences for anxiety-like behaviour in rats, the 
present study did not produce comparable results for these substances alone or in 
combination.  
 
7.0 General Discussion 
The findings of this research did not support the expectation. When adults, adolescent 
rats exposed to BZP and/or ethanol were no different behaviourally from saline controls. 
The following section will discuss the theoretical significance of the results, provide an 
explanation for this finding and suggest improvements to this study. Finally, the 
implications of this research will be discussed.  
 
7.1 Neuronal Imprinting 
 This study intended to demonstrate neuronal imprinting of the substances 
individually and in combination. In other words, it was anticipated that the effects of the 
drug exposure on the developing nervous system would have detrimental effects well into 
adulthood following a sustained period of abstinence. Contrary to expectations, neuronal 
imprinting was generally not demonstrated. However, ethanol-treated females are a 
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possible exception. These animals displayed less ambulation in the open field than saline 
females thereby suggesting that ethanol exposure during adolescence had enduring sex-
related effects which outlasted acute effects of the substance. Therefore, it is possible that 
ethanol-treated females demonstrated neuronal imprinting. Since these subjects did not 
show any other differences it is difficult to determine if they were more anxious or if this 
finding was simply an aberration. Additionally, combined exposure females did not show 
this difference. However, it is not known if BZP attenuated this effect. Clearly, further 
research is required to clarify this outcome. In summary, this research did not find 
support for the neuronal imprinting account of drug exposure as there was a lack of 
behavioural differences during adulthood testing. 
 
7.2 Explanation and Suggestions for Improvement 
 Although the present research did not reveal behavioural differences in adulthood 
(thereby failing to support the neuronal imprinting theory), this does not mean that 
differences would never appear. Therefore, some explanation for why differences were 
not found seems justified especially in the context of how the study differed from 
previous studies. 
 In their study, Aitchison and Hughes (2006) exposed rats to BZP on PND 45 – 55. 
They selected this time of administration to represent exposure during the latter portion 
of adolescent development. In the current study, subjects were treated on PND 41 – 50. 
This period was selected to represent the mid to later stage of adolescent development 
(Andersen, 2003) as this period represents a time when young persons have a high level 
of experimentation with substances (Spear, 2000). Therefore, it is possible the differences 
in results could have arisen from the different periods of brain development when the 
drugs were experienced. 
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Interestingly, past studies on the long-term effects of adolescent exposure to drugs 
have frequently used varying exposure periods. For example, Achat-Mendes et al. (2003) 
administered MDMA or Ritalin to mice on PND 26 – 32. Fone et al. (2002) exposed rats 
to MDMA twice daily on PND 39 – 41. In their study, Sircar & Sircar (2006) treated rats 
daily with ethanol on PND 30 – 36. Finally, Salimov et al. (1996) repeatedly 
administered rat’s ethanol 3 – 8 weeks post natal. Each of these studies found adulthood 
consequences following adolescent exposure. Given that previous research has 
demonstrated adulthood consequences following a variety of adolescent treatment 
periods with both stimulants (e.g. BZP, MDMA, Ritalin) and depressants (e.g. alcohol) it 
seemed likely that the selected period for the present study would yield adulthood 
consequences for the substances alone and in combination. However, this was not the 
case. Therefore, further research which targets different adolescent treatment periods is 
clearly required. 
 In addition to the treatment period, the period of adulthood testing varied between 
this study and Aitchison’s and Hughes’ (2006). In their study, animals received all 
adulthood testing during the 23-day period PND 72 – 95. In the present study, animals 
were tested over two separate four-day periods i.e. early and mid-adulthood. The four 
days of testing at each period were relatively narrow in comparison to their study and to 
the duration of the periods themselves. The early adulthood period extends from PND 70 
to approximately PND 80. In comparison, the mid-adulthood period extends from PND 
110 – 120 (Andersen, 2003). Since the current study only required four days of testing at 
each age, the end of the periods were chosen. The use of limited testing days at specific 
periods is the best explanation for why no differences were found. 
 During behavioural testing Aitchison and Hughes (2006) repeatedly tested 
subjects on each measure (e.g. six times in the light/dark box) throughout the 23 days. 
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Averages for each animal from each test were used to represent their performance (Cassel 
et al., 2005 provides another example of this method). In my opinion, this method 
provided a broader indication of the animal’s behaviour during adulthood rather than a 
specific indication that was employed by the current project. As a result, their testing 
period encompassed an age range which was wide enough to detect adulthood differences 
in behaviour. Therefore, the use of a narrow range of testing ages reduces the chance of 
observing differences which could be apparent across the broader adulthood period. The 
use of broader testing periods would be an improvement on the current study as this 
would provide a better representation of adulthood as a whole. If changes resulting from 
BZP and/or ethanol exposure were to be found, the testing periods could be adjusted to 
specify when the deficits occur and for how long they persist. 
 Given that both BZP and ethanol affect DA and 5-HT transmission, this study 
would have benefited from neurochemical analyses of the brain regions where these 
substances are active (Baumann et al., 2005; Thanos et al., 2005). Differences in the 
functioning of these neurotransmitters might have indicated long-term consequences even 
without the presence of behavioural changes. For example, animals with damage to the 5-
HT system display heightened anxiety compared to controls (Graeff, Viana, & Mora, 
1997). In comparison, abnormal DA activity has been linked to motor control deficits and 
aggressive behaviour (de Almeida, Ferrari, Parmigiani, & Miczek, 2005; Spina et al., 
1998). Therefore, if this study had found altered activity of 5-HT and/or DA in adulthood 
it would indicate that future research would likely find behavioural deficits when 
appropriate testing ages are used. 
 In summary, the use of a narrow range of testing ages is a possible explanation for 
the lack of adulthood behavioural differences. This research would have benefited from 
neurochemical analyses. This would have provided an additional indication of the long-
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term consequences of BZP and ethanol exposure. Future studies should first employ 
wider ranges of testing ages to provide a broad indication of the animal’s adulthood 
behaviour. 
 
7.3 Implications 
This is the first experimental research to assess the longer-term consequences of 
individual and combined effects of adolescent exposure to BZP and ethanol. Neuronal 
imprinting (i.e., the effects of drug exposure outlasting the drug itself) of these substances 
was not found. However, this outcome still has implications for New Zealand society 
given there is much media attention and public debate about the safety of party pills and 
their use with alcohol.  
The most crucial implication of this research is its significance for young people 
who frequently use party pills and alcohol. As discussed earlier, even though the study 
did not reveal adulthood changes in anxiety-like behaviour, it does not mean that other 
differences do not exist. Future studies which address the limitations outlined above are 
more likely to detect any negative outcomes following adolescent exposure to these 
substances. Thus far, using party pills during adolescence has been linked with possible 
heightened anxiety during adulthood (Aitchison & Hughes, 2006). The stimulant drug 
MDMA (‘ecstasy’) which is very similar to BZP has also shown some long-term 
consequences. Young people who use ecstasy have increased chances of developing 
mood disorders latter in life. These include depression and generalized anxiety disorder 
(Fone et al., 2002; Lieb et al., 2002). Additionally, young persons who use ecstasy are 
likely to have an increased responsiveness to the rewarding effects of other drugs (e.g. 
cocaine) later in life (Achat-Mendes et al., 2003). In comparison, young people who 
frequently use alcohol are more likely to have learning difficulties and problems with 
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memory when they are adults (Pascual et al., 2007; Sircar & Sircar; 2005). The effects of 
frequent use of party pills and alcohol on the developing brain are likely to negatively 
impact on the quality of life of the users during adulthood. Therefore, the frequent use of 
these substances by young persons in New Zealand is a major societal issue. The public 
in general should take this and similar future research into consideration when evaluating 
party pills safety and legal status. 
 
8.0 Future Directions 
This study has indicated the direction future research should take. Firstly, the limitations 
of this experiment need to be addressed. Future studies should use broader testing age 
ranges to detect any behavioural differences. When these differences have been observed, 
additional studies could determine if these deficits are maintained through out the life 
span. Neurochemical analyses of brain tissue are required. These analyses will identify 
the neural mechanisms which underlie the deficits associated with adolescent exposure to 
BZP and ethanol.  
 Following BZP exposure, acute hyperactivity and excessive grooming were 
observed but not measured. Although increased ambulation, and head bobbing have been 
found soon after BZP treatment (Baumann et al., 2005) no other research has indicated 
the level of hyperactivity or grooming observed in this study. Additional research which 
investigates this casual observation is justified as such behaviour is stereotypical of the 
acute effects of MDMA exposure (Johnstone et al., 2007). Hypofunctioning of the 
mesolimbic and mesocortical DA system has been associated with the impulsive and 
hyperactive behaviour observed in attention deficit/hyperactivity disorder (Sagvolden, 
2000). Given that BZP has major effects on mesolimbic DA levels (Yarosh et al., 2007), 
it is possible that a similar effect could account for the hyperactivity and excessive 
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grooming observed in the present study. Clearly further research is required to 
substantiate this possibility.  
 Finally, adolescence represents a period of special vulnerability to the enduring 
effects of drugs (Chambers et al., 2003). However, there is limited research on the long 
lasting effects of adolescent drug exposure. Fortunately, this line of research has gained 
momentum over recent years (e.g Achat-Mendes et al., 2003; Aitchison & Hughes, 2006; 
Sircar & Sircar; 2006). The adolescent period deserves special attention as this is when 
individuals are most likely to experiment with drugs (Spear, 2000). Therefore, 
researchers should continue to investigate the effects of periadolescent drug exposure. 
 
9.0 Conclusions 
Substance use by young people is inevitable. Some experimentation with 
substances (e.g. alcohol, nicotine) can be considered a normal part of a young person’s 
development (Arnett, 1992). However, ensuring that young people avoid illicit 
substances is difficult. Legislation informs young people that illicit substances should not 
be taken as they have been deemed harmful and unsafe. However, educating our children 
about the dangers of drug use will always remain our most powerful weapon against 
adolescent substance use. Fortunately, in New Zealand school based programmes which 
address the dangers of drug use exist (e.g. DARE, YES Resources, 2008). These 
programmes should be encouraged by parents and teachers of children who are about go 
through the adolescent period of development. 
The main limitation of the current study was the relatively narrow adulthood 
testing ages. The aim of this study was to demonstrate behavioural differences in 
adulthood following adolescent exposure to BZP and/or ethanol. However, with the 
possible exception of ethanol-treated females, adolescent rats treated with BZP, ethanol, 
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or both did not show behavioural differences in adulthood compared to controls. This 
finding was most likely due to the narrow range of testing ages adopted in the study.  
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AEC Ref: 2007/23R 
 
 
19 September 2008 
 
 
Mr James Perry 
Psychology 
UNIVERSITY OF CANTERBURY 
 
 
Dear Mr Perry 
 
I am pleased to inform you that the Animal Ethics Committee has approved your 
application entitled: “Long-term behavioural effects of benzylpiperazine and its 
interaction with alcohol on adolescent rats” 
 
Approval has been granted: 
 
(a) for the use of a maximum of 80 hooded rats 
(b) for your research project to be undertaken over a period six months from 16 April 
to 31 October 2007.  If you require an extension of this period please contact the 
AEC Secretary. 
 
Please find enclosed a copy of the Animal Welfare (Records and Statistics) Regulations 
1999 for your information. 
 
Also enclosed is a copy of the MAF Animal Manipulation Statistical form (and list of 
Animal Type Codes and brief guideline notes) which you are required to complete and 
return to the Secretary of the AEC (Mrs Deborah Wekking, Level 6 Registry) 30 days 
after the completion of this project, or once every three years, which ever comes first.  If 
no animals have been manipulated in your project please provide a “Nil” return. 
 
 
Yours sincerely 
 
 
 
 
Associate Professor Jim Briskie 
Chair 
Animal Ethics Committee 
 
c.c. Animal Ethics Committee 
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Appendix B 
 
Transitions 
Subjects 
 1 2 3 4 5 6 7 8 
Observer 1 58 50 6 34 0 34 24 25 
Observer 2 58 52 7 38 0 37 26 24 
Observer 3 56 52 8 36 0 34 24 25 
 
 
Corner Occupancy 
Subjects 
 
 1 2 3 4 5 6 7 8 
Observer 1 48.5 35.5 93 51.5 100 27 58 23 
Observer 2 48 33.5 92.5 93 100 27.5 54 19.5 
Observer 3 49 35.5 93 47 100 30 55 21.5 
 
 
Centre Occupancy  
 
Subjects 
 
 1 2 3 4 5 6 7 8 
Observer 1 7.5 18.5 2 5 0 21 6 1 
Observer 2 6.5 20.5 2 4 0 22 6.5 1 
Observer 3 7 20.5 2.5 4.5 0 21.5 7.5 1 
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Appendix B contd. 
 
Rearing 
 
Subjects 
 
 1 2 3 4 5 6 7 8 
Observer 1 24 31 7 27 0 9 14 5 
Observer 2 22 29 10 26 0 12 20 6 
Observer 3 24 28 9 26 0 11 19 5 
 
 
Grooming 
 
Subjects 
 
 1 2 3 4 5 6 7 8 
Observer 1 1 0 0 1 0 4 0 0 
Observer 2 0 0 0 1 0 4 0 0 
Observer 3 1 0 0 0 0 4 0 0 
 
 
 
